Why Sarepta Therapeutics Stock Is Jumping Today
Shares of the rare-disease specialist Sarepta Therapeutics (NASDAQ: SRPT) jumped by as much as 29.6% in pre-market trading Friday morning.
What catalyst provided the spark for this double-digit move higher? After the closing bell Thursday, Sarepta announced that the Food and Drug Administration (FDA) had granted an accelerated approval for the company's Duchenne muscular dystrophy drug (DMD) Vyondys 53. This marks the company's second approval for the rare, genetically based muscle-wasting disease.
Image source: Getty Images.
Source Fool.com
